The recent development of tau specific in vivo staging of Alzheimer’s disease (AD), and more in general of tau pathologies such as Frontotemporal Dementia (FTD), is a compelling target in clinical research in order to track disease changes longitudinally and in the continuum relation to established biomarkers. This evidence concerns the gene MAPT and frontotemporal dementia.